GlassScriptPhysician profile
Merdod Ghafouri
NPI 1811925928
$78,514.26
in general payments reported to CMS, 2019-2025
39 companies · $1,351 in 2025
The $1,351 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,889 · 2020: $576 · 2021: $1,093 · 2022: $11K · 2023: $31K · 2024: $31K · 2025: $1,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $60K · Food and Beverage: $3,699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $60,000.00 |
| Food and Beverage | $3,699.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $69,500.00 | 2022-2024 | Auryon Laser System 100-120 Vac |
| Abbott Laboratories | $1,274.44 | 2019-2024 | Aveir, Amplatzer Amulet, Mitraclip |
| Novartis Pharmaceuticals Corporation | $731.36 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $663.56 | 2020-2025 | Camzyos, Eliquis |
| Pfizer INC. | $558.89 | 2019-2025 | |
| Novo Nordisk INC | $519.80 | 2022-2025 | Wegovy, Ozempic |
| Amgen INC. | $448.33 | 2019-2023 | Repatha |
| Cvrx, INC. | $439.18 | 2021-2025 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $371.89 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $299.76 | 2019-2023 | Xarelto |
| Esperion Therapeutics, INC. | $293.55 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $284.63 | 2019-2023 | |
| Scpharmaceuticals INC. | $259.82 | 2023-2025 | |
| Cardiovascular Systems INC. | $238.66 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $238.30 | 2022-2025 | Verquvo, Capvaxive |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $186.95 | 2019-2022 | |
| Boston Scientific Corporation | $178.63 | 2019-2024 | Lux-Dx Insertable Cardiac Monitor, Watchman Access System |
| Medtronic, INC. | $166.78 | 2025 | Linq II |
| Amarin Pharma, INC. | $155.92 | 2019 | |
| Medtronic Vascular, INC. | $153.54 | 2019-2020 | |
| Atricure, INC. | $149.71 | 2022-2023 | |
| Bridgebio Pharma, INC. | $144.43 | 2025 | Attruby |
| Zoll Respicardia, INC. | $136.39 | 2021 | |
| Lilly USA, LLC | $124.51 | 2025 | |
| Abiomed | $123.84 | 2021 | |
| Ionis Pharmaceuticals, INC. | $122.03 | 2025 | Tryngolza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.97 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $111.97 | 2019-2020 | |
| Kestra Medical Technology Services, INC. | $100.72 | 2023 | Assure Wcd |
| Siemens Medical Solutions USA, INC. | $92.89 | 2021 | |
| Philips North America LLC | $89.05 | 2020-2021 | |
| Actelion Pharmaceuticals US, INC. | $65.54 | 2019 | |
| Depuy Synthes Sales INC. | $32.50 | 2024 | Peak, Monovisc, Orthovisc |
| Medicomp INC | $29.11 | 2023 | Telepatch Cardiac Monitor |
| Recor Medical INC | $28.00 | 2025 | Paradise Ultrasound Renal Denervation System |
| Livanova USA, INC. | $24.82 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $23.71 | 2019 | |
| Cardiofocus, INC. | $17.70 | 2019 | |
| Altathera Pharmaceuticals LLC | $11.38 | 2024 | Sotalol Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Merdod Ghafouri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.